NPI: 1477087658 · ANTIOCH, TN 37013 · Urgent Care Clinic/Center · NPI assigned 04/14/2017
Authorized official HOWORTH, WILLIAM controls 20+ related entities in our dataset. Read more
| Authorized Official | HOWORTH, WILLIAM (PRESIDENT, URGENT CARE) |
| Parent Organization | GALEN HOLDCO, LLC |
| NPI Enumeration Date | 04/14/2017 |
Other providers sharing the same authorized official: HOWORTH, WILLIAM
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 18,279 | $582K |
| 2019 | 18,420 | $913K |
| 2020 | 19,344 | $1.05M |
| 2021 | 37,872 | $2.00M |
| 2022 | 61,055 | $2.71M |
| 2023 | 57,631 | $2.69M |
| 2024 | 30,433 | $1.62M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| S9083 | Global fee urgent care centers | 61,021 | 55,807 | $4.38M |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 38,453 | 31,743 | $2.44M |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 26,462 | 22,801 | $1.51M |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 20,888 | 18,007 | $1.28M |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 11,769 | 10,401 | $882K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 13,804 | 12,434 | $374K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3,200 | 2,825 | $192K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 10,013 | 8,669 | $164K |
| 87428 | 5,675 | 4,946 | $146K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 19,335 | 8,089 | $73K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 16,198 | 13,769 | $42K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 832 | 662 | $27K |
| 99215 | Prolong outpt/office vis | 287 | 260 | $21K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4,112 | 3,336 | $18K |
| 99205 | Prolong outpt/office vis | 140 | 125 | $12K |
| 99201 | 59 | 58 | $4K | |
| 71046 | Radiologic examination, chest; 2 views | 704 | 596 | $4K |
| 81025 | 1,741 | 1,484 | $3K | |
| 81002 | 3,739 | 3,143 | $2K | |
| 73610 | 283 | 243 | $2K | |
| 73630 | 214 | 178 | $1K | |
| 69209 | 121 | 90 | $915.68 | |
| 93000 | 132 | 126 | $724.74 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 162 | 140 | $717.79 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,351 | 1,201 | $567.08 |
| 87807 | 148 | 129 | $478.97 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 599 | 517 | $437.30 |
| 73140 | 65 | 60 | $407.55 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 434 | 388 | $254.98 |
| 73110 | 17 | 13 | $105.21 | |
| 86308 | 69 | 64 | $97.63 | |
| 73130 | 13 | 12 | $42.51 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 47 | 44 | $12.83 |
| 81003 | 139 | 57 | $10.00 | |
| 99000 | 433 | 360 | $7.78 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 16 | 14 | $1.32 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 14 | 13 | $0.96 |
| 99051 | 137 | 128 | $0.00 | |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | 79 | 63 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 129 | 71 | $0.00 |